Detecting and Treating Subclinical Anthracycline Therapy Related Cardiac Dysfunction in Low Income Country.

• Status: Unknown status
• Trial end date: 2021-06-01
• Target enrollment: 0
• Participant gender: All

Summary

The objective of this research is to describe the burden of subclinical anthracycline therapy related cardiac dysfunction( ATRCD) by applying international guideline on Uganda cancer patient and to evaluate the significance of treating subclinical ATRCD with carvedilol.

• Phase: Phase 3
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Makerere University
• Collaborators: Uganda Cancer Institute; University of Cape Town
• Treatments: Carvedilol

Criteria

Inclusion Criteria:

1. Age between and include 18 and 50 years.

2. Newly diagnosed cancer patients who develop subclinical ATRCD during cardiac follow up.

Exclusion Criteria:

1. Patient who has been taking carvedilol prior to the study

2. Patient who self report to be allergic to carvedilol

3. Systolic blood pressure < 90mmHg

4. Heart Rate < 50 beat per minute

5. Patient who is asthmatic or has chronic obstructive lung disease

6. Pregnant woman